Park National Corp OH Buys 954 Shares of Eli Lilly and Company $LLY

Park National Corp OH lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 6.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,528 shares of the company’s stock after purchasing an additional 954 shares during the quarter. Park National Corp OH’s holdings in Eli Lilly and Company were worth $17,967,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of LLY. Bank of America Corp DE acquired a new position in Eli Lilly and Company in the 2nd quarter worth about $13,522,666,000. Jupiter Topco LLC bought a new position in shares of Eli Lilly and Company during the second quarter valued at $4,667,180,000. Fifth Third Bancorp lifted its holdings in shares of Eli Lilly and Company by 321.3% during the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock worth $1,805,959,000 after purchasing an additional 1,497,423 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of Eli Lilly and Company by 353.7% in the first quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company’s stock worth $1,425,859,000 after purchasing an additional 1,208,510 shares during the last quarter. Finally, Corient Private Wealth LP acquired a new stake in Eli Lilly and Company in the second quarter valued at $764,116,000. 82.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 13,500 shares of company stock worth $15,958,170. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Up 1.0%

Shares of LLY stock traded up $11.97 on Monday, reaching $1,154.82. 842,151 shares of the company were exchanged, compared to its average volume of 2,976,150. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The company has a 50-day moving average of $1,176.33 and a 200-day moving average of $1,089.48. The company has a market cap of $1.09 trillion, a price-to-earnings ratio of 38.75, a PEG ratio of 1.40 and a beta of 0.46. Eli Lilly and Company has a one year low of $783.85 and a one year high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same period in the prior year, the business earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts anticipate that Eli Lilly and Company will post 36.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on LLY. Citigroup increased their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Bank of America increased their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Leerink Partners boosted their price target on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Truist Financial lifted their target price on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, HSBC increased their price target on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a report on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,311.96.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA expanded approval of Jaypirca (pirtobrutinib) for previously untreated adults with chronic lymphocytic leukemia or small lymphocytic lymphoma without a 17p deletion. The decision, supported by Phase 3 results, expands Jaypirca’s addressable market and could accelerate sales growth. FDA Expands Approval for Eli Lilly Therapy in Untreated Leukemia Patients
• Positive Sentiment: Lilly’s experimental cancer drug olomorasib received FDA orphan-drug designation for pancreatic cancer. The designation may provide development incentives and highlights Lilly’s effort to broaden its oncology pipeline, though it is not an approval or proof of commercial success. Lilly Expands Oncology Footprint With FDA Win for Pancreatic Cancer Drug
• Positive Sentiment: Lilly expanded its collaboration and licensing agreement with Gate Bioscience to discover medicines aimed at difficult-to-drug proteins. It also partnered with Ginkgo Bioworks on drug discovery, strengthening external innovation efforts and potentially adding to its long-term pipeline. Gate Bioscience Expands Collaboration and License Agreement With Lilly
• Positive Sentiment: Early results for a next-generation obesity treatment targeting the amylin pathway renewed enthusiasm about Lilly’s ability to extend its leadership in the rapidly growing weight-loss market. Reports also point to strong patient growth and market-share gains versus Novo Nordisk. Eli Lilly Targets Amylin Pathway to Unlock Next Generation Obesity Drug Combinations
• Neutral Sentiment: Lilly will present 21 dermatology studies at the Fall Clinical Dermatology Conference, including data on Ebglyss, Taltz and Zepbound. The presentations could support future adoption, but they are not immediate revenue catalysts. Lilly Dermatology Portfolio Data
• Negative Sentiment: At roughly $1.09 trillion in market value and a forward earnings multiple near 39, Lilly’s valuation already reflects substantial obesity-drug growth. Any clinical, regulatory or competitive setback could therefore produce outsized downside.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.